MolBreeding
博瑞迪
MolBreeding (博瑞迪) is a Chinese agricultural biotechnology company that operates as the country's largest CRO in crop and animal breeding . Founded around 2018, the company spent its first six years building a high-throughput, low-cost molecular breeding platform that it says has cut qualified germplasm development cycles by over 50%, improved selection accuracy by 20–30%, and slashed costs by more than 90% compared with traditional solid-phase chip methods . Its liquid-phase chip technology is positioned as solving a core bottleneck for bringing molecular breeding to domestic agriculture .
The company shifted toward a CRO platform model in 2023, offering services tailored to different species and client needs to address the long development cycles, high costs, and uncertainty typical in agriculture . Dalton Venture, which backed MolBreeding in 2023, frames the bet as part of a broader push into seed-industry technology amid China's strategic focus on reducing import dependence in germplasm .吕子岳, MolBreeding's CFO, has described the domestic breeding field as still in a 2.0–3.0 technology phase while developed countries have moved to 4.0 intelligent breeding .
AI-generated — may contain errors, please verify.
Coverage
Dalton Venture's Sun Qi: Building Confidence Through Cyclical Swings, Riding Out Industry Ups and Downs | Dalton Insights
As winter fades and spring arrives, China's venture capital industry's annual opening gala convened as scheduled. On February 28, 2025, the "PEDaily 100" hosted by Zero2IPO and PEDaily took place in Sanya, bringing together the investment community to take the pulse of an unprecedented 2025. **Dalton Venture founding managing partner Sam Gao** was invited to participate in the roundtable discussion ***Healthcare Investment: Against the Current***, sharing Dalton Venture's positioning and thinking in the healthcare sector.
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
Dalton Venture's Sun Qi: Seven Questions We're Pondering "In the Springtime" | Dalton Insights
What should investors do to keep up with the changes of this era?
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
VBData Exclusive | Dalton Venture: The Next Phase of Opportunities in Healthcare — "Technology + Safety" Is the Unavoidable Theme
In a turbulent environment, most investment firms have chosen to play it safe, pulling back on deal activity. Yet in 2023 — widely called a funding winter — Dalton Venture actually picked up its investment pace. How does the firm see 2024 shaping up? At the start of the new year, Sun Qi, founding and managing partner of Dalton Venture, sat down with VBData to share his outlook on healthcare trends for 2024 and his advice for founders.





